Charcot Marie Tooth (CMT) - Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Charcot Marie Tooth (CMT) - Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.
According to this research, the market of Charcot Marie Tooth (CMT) in 7MM was found to be USD 502.75 million in 2016, and is expected to increase from 2016-2027.
The United States accounts for the largest market size of Charcot Marie Tooth (CMT), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Charcot Marie Tooth (CMT) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Disease Understanding & Treatment Algorithm
The exact symptoms of Charcot Marie Tooth (CMT) vary from person to person partly because there are different types of CMT. It may cause muscle weakness, contractures and bone deformities, sensory loss.
The report gives the thorough understanding of the CMT by including details such as disease definition, symptoms, types, causes, genetics and inheritance, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Charcot Marie Tooth (CMT) in the US, Europe, and Japan.
Charcot Marie Tooth (CMT) is one of the most commonly inherited neuropathy in the United States with an estimated prevalence of one in 2,500 as per data released by the National Institutes of Health (NIH). As per data released by the National Organization for Rare Disorders (NORD), the early symptoms of hereditary neuropathy develop gradually sometime in adolescence, early adulthood or middle age and tends to affect an equal number of males and females.
Among the European countries, Germany had the highest prevalent population of CMT with 30,000 cases, followed by France which had prevalent population of 23,414 in 2016. On the other hand, Spain had the lowest diagnosed prevalent population of 16,255 in 2016.
According to this research, total prevalent population of CMT in the 7 major markets estimated approximately 2, 56,934 cases in 2016.
This research estimates that the prevalent population of CMT in 7MM will significantly change during the study period [2016-2027].
This research estimates a higher prevalence of Charcot Marie Tooth (CMT) in the United States with 129,251 cases in 2016.
At present, there are no FDA approved therapies for the treatment of Charcot Marie Tooth (CMT) in the United States and the current therapeutic market for Charcot Marie Tooth (CMT) is based on the supportive management such as occupational therapies, physiotherapy, ankle-foot orthoses (AFO) and shoe inserts.
The expected launch of upcoming therapies such as PXT3003 (Pharnext) and ACE-083 (Acceleron) in 2021 and 2023 respectively have the potential to create a significant positive shift in the Charcot Marie Tooth (CMT) market size.
PXT3003 trial results indicated significant improvement in patients with mild-to-moderate CMT1A and provided encouraging results that indicate PXT3003 may change the treatment paradigm for the disease. Additionally, the candidate has also received Orphan Drug Status from the US FDA and EMA.
The other emerging therapy ACE-083 (Acceleron) is currently under development for the treatment of focal muscle loss. It has been designed to increase strength and function in specific target muscles for improved patient function and quality of life. It is currently under second phase of development for CMT and is also scheduled to enter the market within the forecast period [2018-2027].
Companies FeaturedPharnext Acceleron Pharma MedDay Pharmaceuticals
Key Topics Covered
1. Key Insights
2. Charcot Marie Tooth Market Overview at a Glance
3. Charcot Marie Tooth (CMT): Disease Background and Overview
4. Epidemiology and Patient Population
5. 7MM Total Prevalent Population of Charcot Marie Tooth
6. Country Wise-Epidemiology of Charcot Marie Tooth
8. Unmet Needs
9. Emerging Drugs
10. Charcot Marie Tooth (CMT): 7 Major Market Analysis
11. The United States Market Outlook
12. EU-5 Countries: Market Outlook
13. Market Drivers
14. Market Barriers
For more information about this report visit https://www.researchandmarkets.com/research/glptgq/charcot_marie?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005282/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 10:01 AM/DISC: 11/30/2018 10:01 AM